A Phase II Trial of the MEK Inhibitor Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity
PROTOCOL CHAIRS
- Andrea Gross, MD
A Phase II Trial of the MEK Inhibitor Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity